SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after Sanofi announced its acquisition for $15.50 per share, a move set to bolster Sanofi's adult immunization portfolio with Dynavax's hepatitis B vaccine and a shingles candidate. This news has sparked significant trading volume, with many long-term holders expressing disappointment over the acquisition price while also discussing the company's recent licensing deal for an oral COVID-19 vaccine program.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT CRYPTO is trending amidst strong community discussion, largely fueled by its close association with Coinbase's #base platform and recent listing on Robinhood. Investors are actively debating its potential as a leading perpetual decentralized exchange, emphasizing its RWA trading features and high leverage offerings, despite some volatility and skepticism regarding past performance. The prevailing sentiment anticipates significant growth, positioning AVNT as a key player in the evolving crypto landscape.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending after receiving a Complete Response Letter (CRL) from the FDA for its lead drug candidate, OLC, which cited manufacturing deficiencies at a third-party vendor, not issues with the drug's efficacy or safety. The community is weighing the short-term delay and potential for future dilution against OLC's strong clinical profile and the company's plan to resubmit for possible approval in the first half of the coming year. Many investors see this as a long-term opportunity, emphasizing that the drug's core benefits for dialysis patients remain intact despite regulatory setbacks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as the market digests news of new government contracts and its significant revenue backlog in the high-performance AI computing space. Community discussion is vibrant, with bulls pointing to strong demand and key industry backing, while others express caution regarding its substantial debt and recent insider share divestment.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

DRV is currently trending as the community actively discusses its significant collaboration with Synthetix to develop derivatives on Ethereum, signaling strong foundational growth. Traders are closely watching its 'slow and steady' performance and 'Onchain Matrix' tokenomics, anticipating further upside following recent consolidation and buyback discussions.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is trending amid discussions around its recent strategic financing and the U.S. Department of Energy taking a warrant, which bulls view as a significant derisking event to scale manufacturing for AI data centers and grid demands. While community sentiment is mixed on execution risk and dilution concerns, many anticipate substantial growth in the long-duration energy storage market. The company's unique non-lithium battery technology positions it to capitalize on increasing demand and government incentives, with focus on its path to consistent profitability.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is generating significant community excitement following positive clinical data for its drug Tradipitant in mitigating GLP-1 induced nausea and vomiting, sparking speculation about its role in the rapidly expanding obesity drug market. This, alongside favorable FDA developments for Hetlioz and multiple upcoming PDUFA dates for other pipeline assets, is fueling discussions around the stock's current undervaluation and potential for a significant re-rating or acquisition. Investors are closely watching these catalysts, anticipating a major move for the company.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is generating significant discussion driven by its strategic partnership to integrate at-home exam technology and speculation surrounding substantial government initiatives in rural healthcare. While many express acute frustration regarding current leadership and past capital allocation, a strong bullish contingent believes the company is deeply undervalued and poised for a major rebound as a global leader in the rapidly expanding AI healthcare sector.

StoneCo Ltd. engages in the provision of financial technology solutions. It caters to merchants and partners that conduct electronic commerce across in-store, online, and mobile channels. The firm offers cloud-based technology platform, electronic payments, and automation of business processes at the point-of-sale. The company was founded by André Street de Aguiar in 2000 and is headquartered in George Town, Cayman Islands.

StoneCo Ltd - Ordinary Shares - Class A

StoneCo Ltd

StoneCo is trending following strong recent earnings beats, significant share buyback programs, and the strategic divestiture of its Linx software business to sharpen focus on the core MSMB segment. Community discussion highlights robust operational execution and impressive growth in areas like Pix adoption, alongside an attractive valuation. However, volatility and concerns about Brazil's political climate, including new fintech taxes, remain central to investor sentiment.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is trending following multiple positive regulatory milestones, including recent FDA approvals for expanded uses of its key drugs Libtayo in skin cancer and Eylea HD for retinal vein occlusion, alongside promising late-stage clinical trial results for garetosmab. The community is buzzing with optimism about the company's robust pipeline and a strong earnings beat, with many investors viewing the stock as an undervalued powerhouse despite some lingering concerns regarding manufacturing facility delays.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regional Management (NYSE:RM) Shares Pass Above Two Hundred Day Moving Average - What's Next?

Regional Management (NYSE:RM) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened...

Insider Selling: Regional Management (NYSE:RM) Director Sells 4,420 Shares of Stock

Regional Management Corp. (NYSE:RM - Get Free Report) Director Michael Dunn sold 4,420 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average...

Insider Selling: Regional Management (NYSE:RM) Director Sells $209,026.80 in Stock

Regional Management Corp. (NYSE:RM - Get Free Report) Director Michael Dunn sold 5,580 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold...

Insider Selling: Regional Management (NYSE:RM) Director Sells $165,484.80 in Stock

Regional Management Corp. (NYSE:RM - Get Free Report) Director Michael Dunn sold 4,420 shares of Regional Management stock in a transaction on Tuesday, December 2nd. The shares were sold at an...

Regional Management (NYSE:RM) Share Price Crosses Above 200 Day Moving Average - Should You Sell?

Regional Management (NYSE:RM) Share Price Passes Above 200 Day Moving Average - Time to Sell...

Regional Management (NYSE:RM) CAO Steven Barnette Sells 1,640 Shares

Regional Management Corp. (NYSE:RM - Get Free Report) CAO Steven Barnette sold 1,640 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average...

Steven Barnette Sells 1,640 Shares of Regional Management (NYSE:RM) Stock

Regional Management Corp. (NYSE:RM - Get Free Report) CAO Steven Barnette sold 1,640 shares of the company's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an...

Brandywine Global Investment Management LLC Purchases Shares of 13,280 Regional Management Corp. $RM

Brandywine Global Investment Management LLC purchased a new stake in Regional Management Corp. (NYSE:RM - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing...

Regional Management (NYSE:RM) Downgraded by Wall Street Zen to "Buy"

Wall Street Zen downgraded Regional Management from a "strong-buy" rating to a "buy" rating in a research note on Saturday...

Los Angeles Capital Management LLC Cuts Stock Holdings in Regional Management Corp. $RM

Los Angeles Capital Management LLC reduced its position in Regional Management Corp. (NYSE:RM - Free Report) by 50.7% in the 2nd quarter, according to the company in its most recent 13F filing with...

Regional Management Corp. engages in the provision of consumer financial services. The firm's products include small, large, and retail installment loans. It also offers optional payment and collateral protection insurance products. The company was founded by Richard A. Godley and C. Glynn Quattlebaum on March 25, 1987 and is headquartered in Greer, SC.

Current Price	$40.12
Prev Close	$40.55
Open	$40.56
Dividend Yield	3.53%
50-Day Moving Average	$38.63
Beta	1.16
Avg. Volume	53,249.00
PE Ratio	9.73

52-Week High	$46.00
52-Week Low	$25.41
Market Capitalization	$562.95M
EPS (Annual)	$4.14
Price to Book	1.06
Revenue Per Employee	$276,162.83
Enterprise Value/EBITDA	N/A

RM
Regional Management Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RM News

RMRegional Management Corp